Ramelteon (Rozerem) and Ketamine Therapy | Tovani Health
Rozerem (Ramelteon) — Melatonin receptor agonist (sleep aid)
Verdict at Tovani Health
Compatible; mechanistically a cleaner sleep agent for KAP patients.
Ramelteon and ketamine have no clinically significant interaction. As a melatonin-receptor agonist, ramelteon avoids the GABAergic and antihistaminic effects of benzodiazepines and Z-drugs. Lighter interaction footprint than most sleep agents.
If you take Rozerem regularly and are considering at-home ketamine therapy, the combination is generally safe at therapeutic doses. This page covers the brief pharmacologic context and what we do at intake.
How Rozerem interacts with ketamine
Ramelteon agonizes MT1 and MT2 receptors with higher affinity than endogenous melatonin. No GABA, no histamine, no opioid activity.
What we do at intake
Continue as normal. Take 30 minutes before bedtime as prescribed.
Bottom line
Ramelteon and ketamine have no clinically significant interaction. As a melatonin-receptor agonist, ramelteon avoids the GABAergic and antihistaminic effects of benzodiazepines and Z-drugs. Lighter interaction footprint than most sleep agents.
Frequently Asked Questions
Is ramelteon a better sleep choice than Ambien for KAP?
From an interaction standpoint, yes. Mechanistically lighter and no abuse potential.
Ready to find out if at-home ketamine fits your situation?
We’ll note that you’re on Rozerem (Ramelteon) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.
FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.
Sources
The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.
- Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI.. Clinical Pharmacokinetics. 2016. PMID: 27028535
Comprehensive clinical pharmacokinetics/pharmacodynamics review of ketamine including CYP-mediated drug interactions (CYP3A4, CYP2B6).
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 16, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.